The KANK2 Knockout HEK293T Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the endogenous KANK2 gene in the human HEK293T cell line. As a polyclonal pool, this product contains a heterogeneous mix of genetic edits, creating a robust loss-of-function model that reflects the stochastic nature of CRISPR-mediated gene disruption. This format allows researchers to investigate KANK2-dependent cellular phenotypes without the artifacts that may arise from clonal selection, providing a physiologically relevant system for functional studies.
The HEK293T host cell line is a derivative of human embryonic kidney (HEK293) cells that stably expresses the SV40 large T antigen. This feature promotes episomal replication of transfected plasmids, leading to exceptionally high levels of recombinant protein expression and efficient retroviral production. Due to their rapid proliferation and amenability to standard transfection methods, HEK293T cells are a workhorse for applications ranging from receptor signaling analysis to large-scale functional genomics screens.
KANK2 (KN motif and ankyrin repeat domains 2) functions as a vital scaffold protein that couples integrin adhesion complexes to the actin cytoskeleton. It directly interacts with talin, a core integrin-actin linker, and also associates with beta-catenin and 14-3-3 adaptor proteins. Upon activation by integrin ligation, TGF-beta, or growth factor stimulation, KANK2 acts as a negative regulator of RhoA GTPase, thereby suppressing stress fiber assembly and promoting the turnover of focal adhesions. This inhibition is mediated through reduced myosin light chain phosphorylation and dampened actin polymerization, with downstream effects on focal adhesion kinase (FAK) signaling. Thus, KANK2 sits at a central signaling node connecting the integrin-talin-RhoA-actin axis to control cell migration, adhesion, and cytoskeletal architecture.
Disruption of KANK2 in HEK293T cells generates a powerful model to dissect the molecular basis of adhesion and migration, processes frequently subverted in pathological conditions. In podocytes, KANK2 mutations are associated with steroid-resistant nephrotic syndrome, highlighting its role in maintaining slit diaphragm integrity. In cancer, KANK2 acts as a tumor suppressor, with links to gastric and breast cancer progression. The knockout model allows for uncoupling KANK2-specific functions from the complex adhesion landscape in HEK293T cells, facilitating mechanistic studies and drug target validation.
The KANK2 Knockout HEK293T Polyclonal Cells are compatible with a wide array of experimental approaches. Researchers can perform wound healing and Transwell migration assays to quantify motility, immunofluorescence staining for paxillin or vinculin to visualize focal adhesion structures, and phalloidin staining to assess actin organization. Biochemical verification of RhoA activity via RhoA-GTP pull-downs and Western blotting, combined with co-immunoprecipitation of talin, confirms the disrupted signaling. These cells are invaluable for investigations into cancer metastasis, cytoskeletal dynamics, and podocyte biology related to kidney disease. For further details or to discuss custom applications, please contact Ascent Research.
